Accropeutics’ oral, selective TYK2/JAK1 inhibitor AC-201 has met the primary and key secondary endpoints in a Phase II ...

That’s what Ventyx Biosciences found when it reviewed data from a phase 2 trial of TYK2 inhibitor VTX958 in moderate to severe plaque psoriasis. The San Diego-based biotech reported that the two ...

IL13-PE38QQR is designed to attach to specific receptors on tumor cells that are not present on normal brain cells. The problem with current treatments for brain tumors is that while neurosurgeons ...

Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD anywhere in the world. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family ...

ORLANDO, Fla. — In moderate to severe plaque psoriasis, two highly selective oral TYK2 inhibitors produced a level of response in phase 2 studies suggesting that drugs in this class might rival ...